Time period What may be noticeable What the evidence supports Weeks 1-4 Satiety, appetite changes, nausea, bowel changes, early scale movement Early tolerability period, not the main efficacy endpoint window Weeks 4-12 More consistent appetite suppression and early weight trend Direction of response may become clearer, but individual variance is high Weeks 12-24 Clinically meaningful separation becomes easier to evaluate Phase 2 primary endpoint at 24 weeks showed dose-dependent weight loss Weeks 24-48 Major body-weight reduction window in Phase 2 48-week Phase 2 secondary endpoint showed the largest published Phase 2 changes Weeks 68-104 Longer-term Phase 3 and extension outcomes TRIUMPH program endpoints measure durability over longer windows Weeks 1-4: Early Signals, Not Final Results The first few weeks are usually the wrong window for judging full retatrutide results
Your dose may need to go up based on 4-week progress checks and appetite feedback, but your price won't: flat monthly rates eliminate the financial barrier to dose optimization
Now, it affects approximately one in 1,000 people, according to the educational orthopedic surgery company Ortho Bullets.
List price varies by compound and formulation as of April 2026
The Future of Gut-Focused Metabolic Medicine Research into the gutmetabolic axis is expanding rapidly
After ovulation, semen is collected from the persons partner to separate the healthy sperm
